| 摘要: |
| ［摘要］ 目的 探讨前列地尔联合贝那普利治疗糖尿病肾病蛋白尿患者的临床效果。方法 选取2014-08～2015-10该院收治的86例糖尿病肾病蛋白尿患者作为研究对象，根据治疗方式不同将其分为对照组和观察组，每组43例。对照组给予贝那普利治疗，观察组给予前列地尔联合贝那普利治疗，对比两组治疗效果、治疗前后24 h尿蛋白含量及24 h尿微白蛋白排泄率、不良反应的发生情况等。结果 观察组总有效率为93.0%，明显高于对照组的72.1%，差异有统计学意义（P<0.05）。两组治疗前24 h尿蛋白含量及24 h尿微白蛋白排泄率比较，差异无统计学意义（P>0.05）；治疗后，两组患者24 h尿蛋白含量及24 h尿微白蛋白排泄率均较治疗前降低，但观察组优于对照组，差异有统计学意义（P<0.05）。观察组不良反应发生率为9.3%，低于对照组的11.6%，但差异无统计学意义（P>0.05）。结论 前列地尔联合贝那普利治疗糖尿病肾病蛋白尿患者的临床效果显著，可有效改善患者临床症状，降低尿蛋白含量，改善患者肾功能，提升治疗效果，且安全性高，不良反应少，对提高患者生活质量具有重要意义。 |
| 关键词: 糖尿病肾病 尿蛋白 前列地尔 贝那普利 |
| DOI：10.3969/j.issn.1674-3806.2016.07.15 |
| 分类号:R 587.1 |
| 基金项目: |
|
| Clinical effect of Alprostadil combined with Benazepril on proteinuria associated with diabetic nephropathy |
|
CHEN Qin-hong
|
|
The Third People′s Hospital of Longgang District, Shenzhen, Guangdong 518000, China
|
| Abstract: |
| ［Abstract］ Objective To explore the clinical effect of alprostadil combined with benazepril on the patients with diabetic nephropathy and proteinuria.Methods Eighty-six patients with diabetic nephropathy and proteinuria admitted to our hospital from August 2014 to October 2015 were selected as the research subjects and were divided into the control group and the observation group according to the different treatment methods, with 43 cases in each group. The control group was treated with benazepril, and the observation group was treated with alprostadil combined with benazepril. The contents of urinary protein and the excretion rate of urine albumin were detected before and 24 h after the treatment. The clinical effect and adverse reactions were compared between the two groups.Results The total effective rate of the observation group(93.0%) was significantly higher than that of the control group(72.1%)(P<0.05). There were no significant differences in the contents of urine protein and the excretion rate of urinary miro-albumin between the two groups before the treatment(P>0.05). The contents of urine protein and the excretion rate of urinary micro-albumin in both of the two groups after the treatment were significantly lower than those in both of the two group befor the treatment(P<0.05). The clinical effect of the observation group was better than that of the control group（P<0.05）. There was no significant difference in the incidence of adverse reactions between the observation group(9.3%) and the control group(11.6%)(P>0.05).Conclusion Alprostadil combined with benazepril is safe and effective in the treatment of proteinuria associated with diabetic nephropathy, and effectively improves the clinical symptoms of patients, reduces the content of urinary protein, improves the renal function and the quality of life, and enhances the efficacy with high safety and less adverse reactions in patients with diabetic nephroparty and proteinuria. |
| Key words: Diabetic nephropathy Urine protein Alprostadil Benazepril |
